Published in J Immunol on September 15, 1993
Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med (2007) 1.54
Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun (1996) 1.48
Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in Staphylococcus aureus infection in mice. Infect Immun (1995) 1.44
Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect Immun (1994) 1.18
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption. J Cell Biol (1998) 0.96
IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood (2013) 0.94
Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods (2013) 0.93
Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine. Immunology (2001) 0.92
Antibody buffering of a ligand in vivo. Proc Natl Acad Sci U S A (2004) 0.84
The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. MAbs (2014) 0.82
PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. Int J Pharm (2014) 0.79
Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J Pharmacokinet Pharmacodyn (2013) 0.75
A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies. PLoS One (2016) 0.75
Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana. Nature (1998) 5.91
Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell (1986) 5.79
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
Multiple independent defective suppressor-mutator transposon insertions in Arabidopsis: a tool for functional genomics. Plant Cell (1999) 4.57
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A (1991) 3.21
Sepsis syndromes: understanding the role of innate and acquired immunity. Shock (2001) 3.11
Early Ad-2 transcription units: only promoter-proximal RNA continues to be made in the presence of DRB. Virology (1979) 3.06
Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol (1989) 3.03
Stability of protein pharmaceuticals. Pharm Res (1989) 2.92
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A (1989) 2.87
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol (1990) 2.87
Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A (1991) 2.86
Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol (1997) 2.86
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nat Cell Biol (2001) 2.76
Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest (1992) 2.63
Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science (1988) 2.62
Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res (1974) 2.61
The inhibition by DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells. Cell (1976) 2.60
In situ hybridization analysis of chick embryos in whole mount and tissue sections. Methods Cell Biol (1996) 2.54
Granulomatous mediastinal adenopathy: can endoscopic ultrasound-guided fine-needle aspiration differentiate between tuberculosis and sarcoidosis? Endoscopy (2011) 2.54
A cytokine network in human diploid fibroblasts: interactions of beta-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1. Mol Cell Biol (1987) 2.52
Heterogeneity of poly(I) x poly(C)-induced human fibroblast interferon mRNA species. Nature (1980) 2.49
Human beta 2 interferon and B-cell differentiation factor BSF-2 are identical. Science (1987) 2.37
Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists. Proc Natl Acad Sci U S A (1988) 2.32
Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved. Proc Natl Acad Sci U S A (1986) 2.30
Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J Immunol (1992) 2.29
Transcriptional regulation of the interferon-beta 2/B cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J Immunol (1988) 2.24
Laparoscopic kidney transplantation: an initial experience. Am J Transplant (2011) 2.24
Function search in a large transcription factor gene family in Arabidopsis: assessing the potential of reverse genetics to identify insertional mutations in R2R3 MYB genes. Plant Cell (1999) 2.23
Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol (1989) 2.19
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol (2001) 2.15
The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest (1990) 2.08
ACP Broadsheet No 138: May 1993. Gross examination of uterine specimens. J Clin Pathol (1993) 2.08
Demographics of animal bite victims & management practices in a tertiary care institute in Mumbai, Maharashtra, India. Indian J Med Res (2014) 2.06
IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol (1991) 2.03
Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia (2007) 2.03
Adjustment of intracuff pressure to prevent aspiration. Anesthesiology (1979) 2.02
Olfactory receptor gene cluster on human chromosome 17: possible duplication of an ancestral receptor repertoire. Hum Mol Genet (1994) 2.00
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol (1996) 1.98
Cytokine-induced production of IFN-beta 2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17 beta. J Immunol (1989) 1.98
Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet (1999) 1.98
DRB-induced premature termination of late adenovirus transcription. Nature (1978) 1.98
Tumor necrosis factor-independent IL-6 production during murine listeriosis. J Immunol (1991) 1.97
Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol (1995) 1.94
Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Proc Natl Acad Sci U S A (1979) 1.92
The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells. Curr Biol (1997) 1.88
Superinduction of human fibroblast interferon production: further evidence for increased stability of interferon mRNA. Virology (1978) 1.87
A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II > or =6). Pancreatology (2003) 1.85
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
Human chromosome 7 carries the beta 2 interferon gene. Proc Natl Acad Sci U S A (1986) 1.82
Amniotic fluid interleukin 6 in preterm labor. Association with infection. J Clin Invest (1990) 1.81
Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem (1988) 1.80
Interleukin 1 is a radioprotector. J Immunol (1986) 1.80
Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg (1989) 1.79
Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts. J Exp Med (1987) 1.78
Dominant paternal transmission of Cornelia de Lange syndrome: a new case and review of 25 previously reported familial recurrences. Am J Med Genet (2001) 1.78
Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol (1992) 1.78
5,6-Dichloro-1-Beta-D-ribofuranosylbenzimidazole inhibits initiation of nuclear heterogeneous RNA chains in HeLa cells. Science (1976) 1.77
On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol (1990) 1.75
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol (1989) 1.75
A proposed simple method for measurement in the anterior chamber angle: biometric gonioscopy. Ophthalmology (1999) 1.73
Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J (2001) 1.73
Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol (1974) 1.73
Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol (1993) 1.73
A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol Cell Biol (1989) 1.70
Ligand-mediated assembly and real-time cellular dynamics of estrogen receptor alpha-coactivator complexes in living cells. Mol Cell Biol (2001) 1.67
The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. Crit Care Med (2000) 1.65
Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis (1978) 1.62
Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity. J Immunol (1987) 1.61
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet (1994) 1.58
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest (1992) 1.58
Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. Mol Endocrinol (2000) 1.58
Human casein kinase Idelta phosphorylation of human circadian clock proteins period 1 and 2. FEBS Lett (2001) 1.57
Escherichia coli CdtB mediates cytolethal distending toxin cell cycle arrest. Infect Immun (2001) 1.56
IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. J Immunol (1989) 1.56
Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation (2001) 1.55
Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery (2001) 1.55
Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun (1988) 1.55
Body mass index as a predictive factor of periodontal therapy outcomes. J Dent Res (2013) 1.55
Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer (1997) 1.53
Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest (1992) 1.52
Interferon messenger RNA content of human fibroblasts during induction, shutoff, and superinduction of interferon production. Proc Natl Acad Sci U S A (1977) 1.51
Cytokine signaling--regulation of the immune response in normal and critically ill states. Crit Care Med (2000) 1.50
Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1. J Immunol (1987) 1.50
Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet (1990) 1.50
Protein dynamics during refeeding of protein-depleted rats: effects of increasing amino acid intake by TPN or enteral continuous feeding. J Nutr (1984) 1.50
Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol Chem (1999) 1.49
Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci U S A (2001) 1.49
A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (1993) 1.49
Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes. Infect Immun (1988) 1.48